Skeletal metastases in pancreatic cancer: A retrospective study and review of the literature

Mitesh J Borad, Hamid Saadati, Arun Lakshmipathy, Elizabeth Campbell, Patricia Hopper, Gayle Jameson, Daniel D. Von Hoff, M. Wasif Saif

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: Skeletal metastases represent an underappreciated site of metastasis in patients with pancreatic cancer. Previous reports have estimated the prevalence to range from 5 percent to 20 percent. With the use of gemcitabine and novel targeted agents such as erlotinib, there has been a modest increase in survival in patients with advanced pancreatic cancer. As such, it is anticipated that previously uncommon occurrences such as skeletal metastases will become more frequent. Patients and Methods: Retrospective chart review was conducted at two academic institutions to identify pancreatic cancer patients with skeletal metastases over a two-year period. Results: Seven patients were identified from a database of 323 patients (2.2 percent). All patients had advanced disease and had received prior systemic therapy (range: 1-4 lines, median: 2 lines). Approximately half (57.1 percent) of the patients were symptomatic from their skeletal metastases. The most common sites of skeletal metastases were vertebrae (100 percent), hips (57.1 percent), and ribs (57.1 percent). Both blastic and lytic lesions were noted, with a predominance of blastic lesions (71.4 percent). A majority of patients (71.4 percent) received bisphosphonates as part of their care. Discussion: Skeletal metastases are an uncommon but clinically important occurrence in patients with pancreatic cancer. Clinicians caring for patients with pancreatic cancer should be alert regarding skeletal metastases, due to the morbidity it can cause for these patients (e.g., back pain, fractures, etc.).

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalYale Journal of Biology and Medicine
Volume82
Issue number1
StatePublished - Mar 2009
Externally publishedYes

Fingerprint

gemcitabine
Diphosphonates
Pancreatic Neoplasms
Retrospective Studies
Neoplasm Metastasis
Erlotinib Hydrochloride

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Borad, M. J., Saadati, H., Lakshmipathy, A., Campbell, E., Hopper, P., Jameson, G., ... Saif, M. W. (2009). Skeletal metastases in pancreatic cancer: A retrospective study and review of the literature. Yale Journal of Biology and Medicine, 82(1), 1-6.

Skeletal metastases in pancreatic cancer : A retrospective study and review of the literature. / Borad, Mitesh J; Saadati, Hamid; Lakshmipathy, Arun; Campbell, Elizabeth; Hopper, Patricia; Jameson, Gayle; Von Hoff, Daniel D.; Saif, M. Wasif.

In: Yale Journal of Biology and Medicine, Vol. 82, No. 1, 03.2009, p. 1-6.

Research output: Contribution to journalArticle

Borad, MJ, Saadati, H, Lakshmipathy, A, Campbell, E, Hopper, P, Jameson, G, Von Hoff, DD & Saif, MW 2009, 'Skeletal metastases in pancreatic cancer: A retrospective study and review of the literature', Yale Journal of Biology and Medicine, vol. 82, no. 1, pp. 1-6.
Borad MJ, Saadati H, Lakshmipathy A, Campbell E, Hopper P, Jameson G et al. Skeletal metastases in pancreatic cancer: A retrospective study and review of the literature. Yale Journal of Biology and Medicine. 2009 Mar;82(1):1-6.
Borad, Mitesh J ; Saadati, Hamid ; Lakshmipathy, Arun ; Campbell, Elizabeth ; Hopper, Patricia ; Jameson, Gayle ; Von Hoff, Daniel D. ; Saif, M. Wasif. / Skeletal metastases in pancreatic cancer : A retrospective study and review of the literature. In: Yale Journal of Biology and Medicine. 2009 ; Vol. 82, No. 1. pp. 1-6.
@article{e4c0ce6886844a57a000cf8bbb9fcdc0,
title = "Skeletal metastases in pancreatic cancer: A retrospective study and review of the literature",
abstract = "Background: Skeletal metastases represent an underappreciated site of metastasis in patients with pancreatic cancer. Previous reports have estimated the prevalence to range from 5 percent to 20 percent. With the use of gemcitabine and novel targeted agents such as erlotinib, there has been a modest increase in survival in patients with advanced pancreatic cancer. As such, it is anticipated that previously uncommon occurrences such as skeletal metastases will become more frequent. Patients and Methods: Retrospective chart review was conducted at two academic institutions to identify pancreatic cancer patients with skeletal metastases over a two-year period. Results: Seven patients were identified from a database of 323 patients (2.2 percent). All patients had advanced disease and had received prior systemic therapy (range: 1-4 lines, median: 2 lines). Approximately half (57.1 percent) of the patients were symptomatic from their skeletal metastases. The most common sites of skeletal metastases were vertebrae (100 percent), hips (57.1 percent), and ribs (57.1 percent). Both blastic and lytic lesions were noted, with a predominance of blastic lesions (71.4 percent). A majority of patients (71.4 percent) received bisphosphonates as part of their care. Discussion: Skeletal metastases are an uncommon but clinically important occurrence in patients with pancreatic cancer. Clinicians caring for patients with pancreatic cancer should be alert regarding skeletal metastases, due to the morbidity it can cause for these patients (e.g., back pain, fractures, etc.).",
author = "Borad, {Mitesh J} and Hamid Saadati and Arun Lakshmipathy and Elizabeth Campbell and Patricia Hopper and Gayle Jameson and {Von Hoff}, {Daniel D.} and Saif, {M. Wasif}",
year = "2009",
month = "3",
language = "English (US)",
volume = "82",
pages = "1--6",
journal = "Yale Journal of Biology and Medicine",
issn = "0044-0086",
publisher = "Yale Journal of Biology and Medicine Inc.",
number = "1",

}

TY - JOUR

T1 - Skeletal metastases in pancreatic cancer

T2 - A retrospective study and review of the literature

AU - Borad, Mitesh J

AU - Saadati, Hamid

AU - Lakshmipathy, Arun

AU - Campbell, Elizabeth

AU - Hopper, Patricia

AU - Jameson, Gayle

AU - Von Hoff, Daniel D.

AU - Saif, M. Wasif

PY - 2009/3

Y1 - 2009/3

N2 - Background: Skeletal metastases represent an underappreciated site of metastasis in patients with pancreatic cancer. Previous reports have estimated the prevalence to range from 5 percent to 20 percent. With the use of gemcitabine and novel targeted agents such as erlotinib, there has been a modest increase in survival in patients with advanced pancreatic cancer. As such, it is anticipated that previously uncommon occurrences such as skeletal metastases will become more frequent. Patients and Methods: Retrospective chart review was conducted at two academic institutions to identify pancreatic cancer patients with skeletal metastases over a two-year period. Results: Seven patients were identified from a database of 323 patients (2.2 percent). All patients had advanced disease and had received prior systemic therapy (range: 1-4 lines, median: 2 lines). Approximately half (57.1 percent) of the patients were symptomatic from their skeletal metastases. The most common sites of skeletal metastases were vertebrae (100 percent), hips (57.1 percent), and ribs (57.1 percent). Both blastic and lytic lesions were noted, with a predominance of blastic lesions (71.4 percent). A majority of patients (71.4 percent) received bisphosphonates as part of their care. Discussion: Skeletal metastases are an uncommon but clinically important occurrence in patients with pancreatic cancer. Clinicians caring for patients with pancreatic cancer should be alert regarding skeletal metastases, due to the morbidity it can cause for these patients (e.g., back pain, fractures, etc.).

AB - Background: Skeletal metastases represent an underappreciated site of metastasis in patients with pancreatic cancer. Previous reports have estimated the prevalence to range from 5 percent to 20 percent. With the use of gemcitabine and novel targeted agents such as erlotinib, there has been a modest increase in survival in patients with advanced pancreatic cancer. As such, it is anticipated that previously uncommon occurrences such as skeletal metastases will become more frequent. Patients and Methods: Retrospective chart review was conducted at two academic institutions to identify pancreatic cancer patients with skeletal metastases over a two-year period. Results: Seven patients were identified from a database of 323 patients (2.2 percent). All patients had advanced disease and had received prior systemic therapy (range: 1-4 lines, median: 2 lines). Approximately half (57.1 percent) of the patients were symptomatic from their skeletal metastases. The most common sites of skeletal metastases were vertebrae (100 percent), hips (57.1 percent), and ribs (57.1 percent). Both blastic and lytic lesions were noted, with a predominance of blastic lesions (71.4 percent). A majority of patients (71.4 percent) received bisphosphonates as part of their care. Discussion: Skeletal metastases are an uncommon but clinically important occurrence in patients with pancreatic cancer. Clinicians caring for patients with pancreatic cancer should be alert regarding skeletal metastases, due to the morbidity it can cause for these patients (e.g., back pain, fractures, etc.).

UR - http://www.scopus.com/inward/record.url?scp=64949143741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64949143741&partnerID=8YFLogxK

M3 - Article

C2 - 19325940

AN - SCOPUS:64949143741

VL - 82

SP - 1

EP - 6

JO - Yale Journal of Biology and Medicine

JF - Yale Journal of Biology and Medicine

SN - 0044-0086

IS - 1

ER -